{
    "nct_id": "NCT06140524",
    "official_title": "Phase 2 Dose-Ranging and Interception Study of Linvoseltamab in Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma",
    "inclusion_criteria": "1. HR-MGUS or NHR-SMM as defined in the protocol\n2. Eastern Cooperative Oncology Group (ECOG) performance status ≤1\n3. Adequate hematologic and hepatic function, as described in the protocol\n4. Estimated glomerular filtration rate (GFR) ≥30 mL/min/1.73 m2 by the modification of diet in renal disease (MDRD) equation\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. High-risk SMM, as defined in the protocol\n2. Evidence of any of myeloma-defining events, as described in the protocol\n3. Diagnosis of systemic light-chain amyloidosis, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), solitary plasmacytoma, or symptomatic MM\n4. Clinically significant cardiac or vascular disease within 3 months of study enrollment, as described in the protocol\n5. Any infection requiring hospitalization or treatment with IV anti-infectives within 28 days of the first dose of linvoseltamab\n6. Uncontrolled human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection; or other uncontrolled infection or unexplained signs of infection\n\nNOTE: Other protocol defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": "Key"
}